UTRN and Duchenne muscular dystrophy: A potential compounding issue with a μUtrn therapeutic for DMD is whether endogenous utrophin could influence the expression, localization, and inherent functional capacity of μUtrn, with utrophin being generally present at low levels on the sarcolemma and also highly concentrated within the neuromuscular and myotendinous junctions [60–62].